Team Work: Pfizer, Abbott Gain Swift Approvals For Lung Cancer Drug/Test Combo

Following simultaneous and swift FDA approvals, Abbott Molecular Diagnostics is launching its Vysis ALK molecular test to identify the small percentage of non-small-cell lung cancer patients who would respond to Pfizer’s Xalkori (crizotinib) cancer drug.